BioCentury
ARTICLE | Company News

Feinstein grants Applied Immunotherapeutics rights to HMGB1 candidates

July 28, 2017 7:51 PM UTC

The Feinstein Institute for Medical Research (Manhasset, N.Y.) granted Applied Immunotherapeutics Inc. (Morris, Conn.) exclusive, worldwide rights to three preclinical candidates. Applied Immunotherapeutics gained rights to 2G7, a mAb against high mobility group box 1 (HMGB1), which is slated to enter Phase I testing in early 2018 to treat anemia of chronic disease. The company also gained rights to K557 and K883, both small molecule inhibitors of HMGB1. The 2G7 licensor group included Professor Ulf Andersson from Karolinska Institute (Stockholm, Sweden).

Other potential indications for the three candidates include rheumatoid arthritis (RA), lupus, inflammatory bowel disease (IBD), diabetes and other inflammation-related diseases. ...